Summary of Lifecore Biomedical Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Revenues: $35.7 million, a 10% increase from $32.6 million in Q4 2024.

7-Month Transition Period Revenues: $75.5 million, a 20% increase from $63 million in the prior year.

Gross Profit Q4 2025: $12.8 million, up from $11.1 million in Q4 2024.

Adjusted EBITDA Q4 2025: $8.6 million, an increase from $6.5 million in Q4 2024.

Net Loss Q4 2025: $5.1 million ($0.16 per share), improved from a loss of $6.6 million ($0.25 per share) in Q4 2024.

Liquidity: Approximately $39 million, including $17.5 million in cash and $21 million available under a revolver.

2Strategic Updates and Business Highlights

Lifecore is focused on achieving a 12% revenue CAGR and improving EBITDA margins to above 25% in the midterm.

Successful expansion in the aseptic fill/finish market, with qualification of a 5-head isolator filler for European and Asian markets.

Added multiple high-value programs to the late-stage pipeline, including two commercial site transfers expected to generate revenue within 24-30 months.

Revamped business development strategy has led to five new programs in 2025, enhancing both the number and quality of customer wins.

Continued improvements in operational efficiencies and cost controls are expected to drive future margin enhancements.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $120 million and $125 million.

2026 Net Loss Guidance: Anticipated between $28.9 million and $33.4 million.

2026 Adjusted EBITDA Guidance: Projected between $20.5 million and $25 million.

Long-term expectations remain optimistic, with significant revenue growth anticipated from 2027 onwards, driven by customer expansions and late-stage pipeline commercialization.

4Bad News, Challenges, or Points of Concern

Anticipated loss of a customer due to a change in supply chain strategy, which will impact revenue.

A delay in a commercial launch from 2026 to 2028 due to customer funding challenges.

Adjusted launch timelines for late-stage programs have been pushed from 2026-2029 to 2027-2030, attributed to external factors beyond Lifecore's control.

The company faces challenges related to customer concentration and the potential impact of financing market fluctuations.

5Notable Q&A Insights

Lifecore's strategy for targeting Asian customers is primarily reactive, with inbound inquiries rather than proactive outreach.

Confidence in delayed commercial launches is bolstered by the program's existing success in other markets.

Further operational efficiencies are expected, particularly in procurement and organizational processes.

The fill/finish capacity landscape is tight for prefilled syringes and cartridges, which Lifecore aims to capitalize on with its technical capabilities.

Free cash flow is expected to exceed $10 million in 2026, with CapEx projected around $8 million. Overall, Lifecore Biomedical demonstrated strong financial performance in 2025, with a focus on strategic growth initiatives and operational efficiencies, despite facing some headwinds and challenges in customer dynamics and market conditions.